These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 22736912)
1. Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases. Pichai MV; Ferguson LR World J Gastroenterol; 2012 Jun; 18(23):2895-901. PubMed ID: 22736912 [TBL] [Abstract][Full Text] [Related]
2. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623 [TBL] [Abstract][Full Text] [Related]
3. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. Takedatsu H; Mitsuyama K; Torimura T World J Gastroenterol; 2015 Oct; 21(40):11343-52. PubMed ID: 26525603 [TBL] [Abstract][Full Text] [Related]
4. [Changing paradigm in the management of inflammatory bowel disease]. Jang BI Korean J Gastroenterol; 2015 May; 65(5):268-72. PubMed ID: 25998972 [TBL] [Abstract][Full Text] [Related]
5. Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland. Guilcher K; Fournier N; Schoepfer A; Schibli S; Spalinger J; Braegger C; Nydegger A; Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1159-1167. PubMed ID: 29985208 [TBL] [Abstract][Full Text] [Related]
6. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study. Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788 [No Abstract] [Full Text] [Related]
7. Conventional medical management of inflammatory bowel disease. Burger D; Travis S Gastroenterology; 2011 May; 140(6):1827-1837.e2. PubMed ID: 21530749 [TBL] [Abstract][Full Text] [Related]
8. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. Suskind DL; Wahbeh G; Burpee T; Cohen M; Christie D; Weber W J Pediatr Gastroenterol Nutr; 2013 Mar; 56(3):277-9. PubMed ID: 23059643 [TBL] [Abstract][Full Text] [Related]
9. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Bonapace CR; Mays DA Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055 [TBL] [Abstract][Full Text] [Related]
10. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies. de Lima-Karagiannis A; Zelinkova-Detkova Z; van der Woude CJ Am J Gastroenterol; 2016 Sep; 111(9):1305-12. PubMed ID: 27349339 [TBL] [Abstract][Full Text] [Related]
11. Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. Geisz M; Ha C; Kappelman MD; Martin CF; Chen W; Anton K; Sandler RS; Long MD Inflamm Bowel Dis; 2016 Jun; 22(6):1435-41. PubMed ID: 26978725 [TBL] [Abstract][Full Text] [Related]
12. Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease: a narrative review. Ardekani ZM; Lorenzo-Leal AL; Bach H Nanomedicine (Lond); 2024 Jan; 19(2):163-179. PubMed ID: 38284393 [No Abstract] [Full Text] [Related]
13. New strategies in the management of inflammatory bowel disease. Rutgeerts P; Baert F Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385 [TBL] [Abstract][Full Text] [Related]
14. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163 [TBL] [Abstract][Full Text] [Related]
15. Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease. Cappello M; Licata A; Calvaruso V; Bravatà I; Aiello A; Torres D; Della Corte V; Tuttolomondo A; Perticone M; Licata G; Craxì A; Cammà C Eur J Intern Med; 2017 Jan; 37():83-89. PubMed ID: 27773555 [TBL] [Abstract][Full Text] [Related]
16. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
17. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Pearce CB; Duncan HD; Timmis L; Green JR Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998 [TBL] [Abstract][Full Text] [Related]